Tagged with drug

Pharma A physician sending off a quick update to a patient via smartphone; a medical caretaker receiving an alert message that a patient’s medical device requires immediate attention. These are no longer hypothetical ideas of healthcare in the distant future, but very real innovations currently being rolled out and integrated across…

Pharma While assessing patient perspectives in comprehensive drug and treatment analyses may sound like a contemporary issue, the Mapi Group has been a pioneer in the practice for over forty years. Mapi Chairman Bernard Jambon explains the importance of patient incorporation in drug and therapy evaluation and his ambitions to expand…

Pharma The Dedicated Chair of the Pharmaceutical Committee of the Association of Health Insurance Companies speaks about drug pricing procedures, the partnership with the pharmaceutical industry, as well as her overarching vision for the organization. The Association of Health Insurance Companies of the Czech Republic (CR CAP) was established in 1997…

Pharma Ahead of the imminent acquisition of Baxalta by Shire, country managing director Italy Fabio Andreola shares his perspective on the rare-disease environment in Italy and how Baxalta will contribute to making the new combined company the undisputed leader in the treatment of rare diseases. How would you assess the Italian…

Pharma The following chart shows the massive potential in the Dutch pharmaceuticals and healthcare markets; a population of almost 17 million with high per capita GDP where a large percentage of the population have long-term health conditions. Click here to read more articles and interviews from the Netherlands, and to download…

Pharma As Egypt continues to grapple with the proliferation of the hepatitis C virus, fresh treatment, prevention and market access pathways are now being applied. Given the severity of Egypt’s hepatitis C epidemic, the national campaign against viral hepatitis remains Egypt’s top healthcare priority. According to Roche’s regional general manager, Ehab…

Pharma Having successfully accomplished a four-year turnaround exercise and with a fresh capital injection from a leading Italian PE firm, SIFI executive chairman Fabrizio Chines has ambitious growth objectives for the coming years, and is investing in R&D projects including the development of an ophthalmic orphan drug. The Italian pharmaceutical industry…

Pharma Alexander Zehnder discusses Sanofi’s sizable contribution to the Italian economy, manufacturing in Italy, and the country’s labyrinthine drug approval processes. What have been your main areas of focus and priorities since your appointment as head of Sanofi’s Italy and Malta operations in October 2014? Sanofi is in the midst of a transition from…

Pharma Laurent Levy, CEO at Nanobiotix, is leading the way in nanomedicine with new market-disruptive developments, establishing a growing presence in European and global research labs and pushing back the frontiers in healthcare, for the industry and for patients. What is the main focus of your work at Nanobiotix, a company you co-founded 12 years ago,…

Pharma Novartis Italy’s Georg Schroeckenfuchs discusses the impact of the company’s global restructuring on the Italian affiliate, the significance of local manufacturing, new products, and how the Novartis has managed to become a market leader in Italy. A lot has been happening with Novartis globally lately: with big changes to the…

Pharma Former Egyptian Minister of Health Adel Adawy discusses the reforms needed in the Egyptian healthcare system and the progress made in the fight against HCV over the last two years. What structural changes need to be made in the Egyptian healthcare system? First of all, Egypt needs to have three…

Pharma “My primary concern is not the current economic situation, but rather the fact that there does not appear to be a clear vision for how Egypt can overcome these challenges and set the economy on a stronger growth trajectory,” says October Pharma CEO Ahmed Zaghloul You were last interviewed by…